Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > APP Announces FDA Acceptance of New Drug

May 10th, 2004

APP Announces FDA Acceptance of New Drug

Abstract:
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New nanoparticle could make cancer treatment safer, more effective: Scientists create a tiny particle for use with focused ultrasound on solid tumors May 16th, 2025

Low-cost formulation reduces dose and increases efficacy of drug against worms: Praziquantel, usually administered in large tablets, is the only anthelmintic available on the market. New form of presentation uses nanotechnology and facilitates use by children and pets May 16th, 2025

Sugar-coated nanotherapy dramatically improves neuron survival in Alzheimer’s model: New treatment traps, neutralizes toxic proteins to stop disease progression May 16th, 2025

Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books



NNN
The Hunger Project